Bree

Pre-eclampsia (PE) is a pregnancy condition marked by high blood pressure (greater than 140/90 mm Hg) and significant protein in the urine after 20 weeks of pregnancy. It affects about 5-8% of pregnant women worldwide and can lead to serious complications for both the mother and child if left untreated. Researchers are investigating cardiovascular changes during pregnancy to improve early detection and treatment of PE, focusing on women at high risk. This study involves pregnant women starting at 10 weeks of pregnancy. At 10 and 20 weeks, participants will have several measurements including NICCOMO (an impedance cardiograph), Maternal Venous Doppler Echography, Maltron bio-electronic impedance analysis, blood pressure, activity tracking, and weight monitoring. If abnormal results appear at 20 or 30 weeks, participants will join a remote monitoring program using devices such as a wireless blood pressure monitor (twice daily), an activity tracker (day and night), and a smart body analyzer for weight (once daily). Participants will be monitored through repeated assessments at 10, 20, and potentially 30 weeks of pregnancy. These include heart and vein imaging, blood pressure checks, activity tracking, and weight measurements. The study aims to track cardiovascular health and detect early signs of PE. Up to 2000 pregnant women from eight hospitals will take part, with ongoing remote monitoring for those showing abnormal test results to support intensive follow-up and care.